DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced that Atherotech Diagnostics Lab will carry its AspirinWorks® Test for determining aspirin effect. Under terms of the agreement, Corgenix’ AspirinWorks product will be used to assess aspirin effect as part of Atherotech Diagnostic Lab’s cardiometabolic testing products. AspirinWorks is the only U.S. FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect.
